2012
YM155 sensitivity in pediatric acute lymphoblastic leukemia.
Chang B, Jemal A, Tyner J, Thayer M, Muschen M, Druker B. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal Of Clinical Oncology 2012, 30: 9555-9555. DOI: 10.1200/jco.2012.30.15_suppl.9555.Peer-Reviewed Original ResearchPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaPhase I/II studyNCI standard riskStandard intensive chemotherapyProtein expressionSubset of patientsAdditional therapeutic agentsB-cell malignanciesYM155 treatmentIntensive chemotherapyII studyPhospho-flow cytometryPrimary patientsCombination therapyAnnexin V bindingTarget effectsNovel agentsPossible efficacyHigh riskStandard riskIsobologram analysisMultiple protein expressionMalignant cells
2011
Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia
Jemal A, Tyner J, Thayer M, Muschen M, Druker B, Chang B. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. Blood 2011, 118: 2490. DOI: 10.1182/blood.v118.21.2490.2490.Peer-Reviewed Original ResearchPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaPatient samplesPrimary patientsCell linesActivation of apoptosisPediatric B-cell precursorHematopoietic stem cell transplantSelective survivin suppressantStandard intensive chemotherapyEarly phase I studiesSubset of patientsStem cell transplantPhase I studiesCommon pediatric malignancyB-cell malignanciesPrimary patient samplesB cell precursorsLymphoblastic cell linesAdditional therapyIntensive chemotherapyCell transplantCombination therapyPediatric malignancies